Buzzard Pharmaceutical

Executive Summary

Buzzard Pharmaceutical is a clinical-stage biotech based in Stockholm, Sweden, focused on developing next-generation IL-1 targeted therapies. Its lead asset, isunakinra, is a potent IL-1 inhibitor designed to treat inflammation-driven diseases, with an initial emphasis on oncology. The company is advancing isunakinra in combination with checkpoint inhibitors, aiming to overcome immunotherapy resistance by modulating the tumor microenvironment. Preclinical data suggest that IL-1 blockade can enhance antitumor immunity, positioning isunakinra as a potential complementary agent in immuno-oncology. As a privately held company, Buzzard has not disclosed its funding history but continues to progress its programs through Phase 2 trials. The company represents an emerging player in the IL-1 targeting space, with a differentiated approach focused on cancer rather than inflammatory diseases, where IL-1 inhibitors are already established.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for isunakinra in combination with checkpoint inhibitor40% success
• H1 2027Potential partnership or licensing deal for oncology indications30% success
• Q2 2026Initiation of Phase 2 trial in additional tumor type70% success